Effect of Pramlintide on Prandial Glycemic Excursions During Closed-Loop Control in Adolescents and Young Adults With Type 1 Diabetes

被引:104
作者
Weinzimer, Stuart A. [1 ]
Sherr, Jennifer L. [1 ]
Cengiz, Eda [1 ]
Kim, Grace [1 ]
Ruiz, Jessica L. [1 ]
Carria, Lori [1 ]
Voskanyan, Gayane [2 ]
Roy, Anirban [2 ]
Tamborlane, William V. [1 ]
机构
[1] Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06510 USA
[2] Medtron Diabet, Northridge, CA USA
基金
美国国家卫生研究院;
关键词
HUMAN AMYLIN ANALOG; POSTPRANDIAL GLUCOSE EXCURSIONS; RANDOMIZED CONTROLLED-TRIAL; INSULIN DELIVERY; ARTIFICIAL PANCREAS; WEIGHT CONTROL; MELLITUS; THERAPY; GLUCAGON; ADJUNCT;
D O I
10.2337/dc12-0330
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE-Even under closed-loop (CL) conditions, meal-related blood glucose (BG) excursions frequently exceed target levels as a result of delays in absorption of insulin from the subcutaneous site of infusion. We hypothesized that delaying gastric emptying with preprandial injections of pramlintide would improve postprandial glycemia by allowing a better match between carbohydrate and insulin absorptions. RESEARCH DESIGN AND METHODS-Eight subjects (4 female; age, 15-28 years; A1C, 7.5 +/- 0.7%) were studied for 48 h on a CL insulin-delivery system with a proportional integral derivative algorithm with insulin feedback: 24 h on CL control alone (CL) and 24 h on CL control plus 30-mu g premeal injections of pramlintide (CLP). Target glucose was set at 120 mg/dL; timing and contents of meals were identical on both study days. No premeal manual boluses were given. Differences in reference BG excursions, defined as the incremental glucose rise from premeal to peak, were compared between conditions for each meal. RESULTS-CLP was associated with overall delayed time to peak BG (2.5 +/- 0.9 vs. 1.5 +/- 0.5 h; P < 0.0001) and reduced magnitude of glycemic excursion (88 +/- 42 vs. 113 +/- 32 mg/dL; P = 0.006) compared with CL alone. Pramlintide effects on glycemic excursions were particularly evident at lunch and dinner, in association with higher premeal insulin concentrations at those mealtimes. CONCLUSIONS-Pramtintide delayed the time to peak postprandial BG and reduced the magnitude of prandial BG excursions. Beneficial effects of pramlintide on CL may in part be related to higher premeal insulin levels at lunch and dinner compared with breakfast.
引用
收藏
页码:1994 / 1999
页数:6
相关论文
共 28 条
[21]   Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin [J].
Riddle, Matthew ;
Frias, Juan ;
Zhang, Bei ;
Maier, Holly ;
Brown, Carl ;
Lutz, Karen ;
Kolterman, Orville .
DIABETES CARE, 2007, 30 (11) :2794-2799
[22]   The role of prandial pramlintide in the treatment of adolescents with type 1 diabetes [J].
Rodriguez, Luisa M. ;
Mason, Kimberly J. ;
Haymond, Morey W. ;
Heptulla, Rubina A. .
PEDIATRIC RESEARCH, 2007, 62 (06) :746-749
[23]   Feasibility of automating insulin delivery for the treatment of type 1 diabetes [J].
Steil, Garry M. ;
Rebrin, Kerstin ;
Darwin, Christine ;
Hariri, Farzam ;
Saad, Mohammed F. .
DIABETES, 2006, 55 (12) :3344-3350
[24]   The Effect of Insulin Feedback on Closed Loop Glucose Control [J].
Steil, Garry M. ;
Palerm, Cesar C. ;
Kurtz, Natalie ;
Voskanyan, Gayane ;
Roy, Anirban ;
Paz, Sachiko ;
Kandeel, Fouad R. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (05) :1402-1408
[25]   Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus [J].
Vella, A ;
Lee, JS ;
Camilleri, M ;
Szarka, LA ;
Burton, DD ;
Zinsmeister, AR ;
Rizza, RA ;
Klein, PD .
NEUROGASTROENTEROLOGY AND MOTILITY, 2002, 14 (02) :123-131
[26]   Fully automated closed-loop insulin delivery versus sermautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas [J].
Weinzimer, Stuart A. ;
Steil, Garry M. ;
Swan, Karena L. ;
Dziura, Jim ;
Kurtz, Natalie ;
Tamborlane, Williani V. .
DIABETES CARE, 2008, 31 (05) :934-939
[27]   Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes - A dose-timing study [J].
Weyer, C ;
Gottlieb, A ;
Kim, DD ;
Lutz, K ;
Schwartz, S ;
Gutierrez, M ;
Wang, Y ;
Ruggles, JA ;
Kolterman, OG ;
Maggs, DG .
DIABETES CARE, 2003, 26 (11) :3074-3079
[28]   A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes [J].
Whitehouse, F ;
Kruger, DF ;
Fineman, M ;
Shen, L ;
Ruggles, JA ;
Maggs, DG ;
Weyer, C ;
Kolterman, OG .
DIABETES CARE, 2002, 25 (04) :724-730